Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecanemab (BAN2401) in Early Alzheimer's Disease
jRCT2080223117Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (7 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Safety and tolerability of lecanemab in early Alzheimer's disease (core study), Efficacy of lecanemab in early Alzheimer's disease (core study) and 1 more. Started Oct 2015; status: completed.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080223117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223117.